Interim Results Positive for Takeda Blood Cancer Med Ixazomib

Takeda Announces That the First Interim Analysis of the Phase 3 Study of Oral Ixazomib in Patients with Relapsed or Refractory Multiple Myeloma Met the Primary Endpoint of Improvement in Progression-Free Survival CAMBRIDGE, Mass. & OSAKA, Japan-- --Takeda Pharmaceutical Company Limited today announced that the randomized, double-blind, placebo-controlled TOURMALINE-MM1 pivotal Phase 3 trial evaluating the safety and efficacy of ixazomib, the first oral proteasome inhibitor, conducted in patients with relapsed or refractory multiple myeloma achieved its primary endpoint of improving progression-free survival at the first pre-specified interim analysis.

http://ift.tt/1CdaKLs